{"id":937265,"date":"2026-02-17T11:37:38","date_gmt":"2026-02-17T16:37:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-utility-of-bioaffinity-technologies-cypath-lung-test-demonstrated-in-real-world-case-study\/"},"modified":"2026-02-17T11:37:38","modified_gmt":"2026-02-17T16:37:38","slug":"clinical-utility-of-bioaffinity-technologies-cypath-lung-test-demonstrated-in-real-world-case-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-utility-of-bioaffinity-technologies-cypath-lung-test-demonstrated-in-real-world-case-study\/","title":{"rendered":"Clinical Utility of bioAffinity Technologies\u2019 CyPath\u00ae Lung Test Demonstrated in Real-World Case Study"},"content":{"rendered":"

<\/p>\n

Clinical Utility of bioAffinity Technologies\u2019 CyPath\u00ae Lung Test Demonstrated in Real-World Case Study<\/b><\/p>\n

Noninvasive CyPath\u00ae Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters<\/i><\/b><\/p>\n

Case study highlights how CyPath\u00ae Lung reduces patient anxiety and supports physician confidence in assessment of benign pulmonary nodules<\/i><\/b><\/p>\n

SAN ANTONIO, Texas–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW)<\/b>,a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a new clinical case study demonstrating how CyPath\u00ae Lung, its noninvasive diagnostic test for lung cancer, supported clinical decision-making in a high-risk patient with multiple pulmonary nodules.<\/p>\n

\nThe 59-year-old patient had a 30-year, three packs per day smoking history and underlying chronic obstructive pulmonary disease (COPD). Imaging revealed multiple scattered pulmonary nodules measuring between 3\u20137 mm and categorized as Lung-RADS 3 on the Lung Imaging Reporting and Data System (Lung-RADS), indicating a probably benign condition.<\/p>\n

\n\u201cDetermining appropriate care for a patient with multiple nodules and a significant smoking history is often complicated by patient anxiety and concern about an ongoing risk of malignancy,\u201d said Daya Nadarajah, MD, the patient\u2019s pulmonologist. \u201cFollow-up can be problematic without the additional diagnostic information provided by CyPath\u00ae Lung. A negative CyPath\u00ae Lung result helps reassure both physician and patient that an early cancer is unlikely to have been missed.\u201d<\/p>\n

\nDr. Nadarajah ordered a CyPath\u00ae Lung test for his patient, which returned a negative result of \u201cunlikely malignancy.\u201d The CyPath\u00ae Lung score gave both physician and patient additional confidence to continue a serial six-month CT surveillance schedule, consistent with Lung-RADS 3 recommendations. In a follow-up CT scan, the sub-centimeter nodules remained stable.<\/p>\n

\n\u201cPatients with multiple small nodules and many years of tobacco use often face months of uncertainty and fear,\u201d said Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer. \u201cCyPath\u00ae Lung provides physicians with additional, objective information that helps stratify risk and supports confident clinical decision-making while maintaining appropriate vigilance for patients at high risk for lung cancer.\u201d<\/p>\n

Supporting Confident, Noninvasive Management<\/b><\/p>\n

\nThis case illustrates the benefit of using CyPath\u00ae Lung as an adjunctive diagnostic tool for managing indeterminate pulmonary nodules \u2013 particularly in high-risk smokers \u2013 by:<\/p>\n